Merck & Co., Inc.

MRK

US58933Y1055

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).

Sector

Pharmaceuticals

Calendar

2024-07-30 - Q2 2024 Earnings Release

Related indices

Dow Jones Industrial , S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

127.5 USD

Average target price

142.7 USD

Spread / Average Target

+11.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MERCK & CO., INC.	+16.95%	323B
ELI LILLY AND COMPANY	+51.82%	797B
NOVO NORDISK A/S	+40.05%	628B
ABBVIE INC.	+9.49%	300B
ASTRAZENECA PLC	+16.68%	244B
ROCHE HOLDING AG	+0.53%	223B
NOVARTIS AG	+9.46%	214B
AMGEN INC.	+5.30%	163B
PFIZER, INC.	-6.29%	153B
SANOFI	-2.35%	118B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2024-06-17 EDT			5-day change	1st Jan Change
127.5 ^USD	-1.53%		-3.03%	+16.95%

12:10am	Merck Gets FDA Approval for Keytruda Plus Carboplatin and Paclitaxel for Endometrial Carcinoma Treatment	MT
06-17	Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer	DJ

Merck Gets FDA Approval for Keytruda Plus Carboplatin and Paclitaxel for Endometrial Carcinoma Treatment	06:10pm	MT
Merck Get FDA Approval for Keytruda to Treat Endometerial Cancer	06-17	DJ
US FDA approves Merck's pneumococcal vaccine for adults	06-17	RE
FDA Approves Merck's Vaccine For Adult Invasive Pneumococcal Disease	06-17	DJ
High-risk health workers can get routine Ebola vaccine, Gavi says	06-13	RE
AbbVie inks immune disorder drug licensing deal with China's FutureGen	06-13	RE
High-risk health workers can get routine Ebola vaccine, says Gavi	06-13	RE
Merck looks for next-generation opportunities in cardiometabolic drugs	06-11	RE
Merck & Co., Inc. to Seek Acquisitions	06-11	CI
Transcript : Merck & Co., Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM	06-11
HSBC Adjusts Price Target on Merck & Co. to $130 From $118, Keeps Hold Rating	06-05	MT
Transcript : Merck & Co., Inc. Presents at 2024 American Society of Clinical Oncology Annual Meeting, Jun-03-2024 06:00 PM	06-03
Merck: promising results in melanoma treatment	06-03	CF
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial	06-03	DJ
Moderna, Merck Say 3-Year Data for Melanoma Combination Therapy Show Continued Improvement in Recurrence-Free Survival	06-03	MT
Moderna & Merck Announces 3-Year Data for mRNA-4157 in Combination with KEYTRUDA (Pembrolizumab)	06-03	CI
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up	06-03	RE
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	06-03	MT
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival	05-31	RE
Sector Update: Health Care	05-31	MT
Declaration of Voting Results by Merck & Co	05-30	CI
Declaration of Voting Results by Merck & Co	05-30	CI
Declaration of Voting Results by Merck & Co	05-30	CI
Declaration of Voting Results by Merck & Co	05-30	CI
US Equities Markets Close Lower Thursday After Q1 Economic Growth Found to be Slower Than Projected	05-30	MT

Merck & Co., Inc.

Equities

MRK